openPR Logo
Press release

myriamed supports local soccer club

10-19-2020 12:53 PM CET | Health & Medicine

Press release from: myriamed GmbH

myriamed supports local soccer club

myriamed supports local soccer club

myriamed supports the local soccer club SV Puma with a small donation to help them buy new sportswear. We hope that the COVID-19 pandemic will be over soon and team sports can take place again.

About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.
myriamed gives access to the following expertise:

• high quality human iPSC-derived somatic cells (myrCell) to be used in drug discovery and development.

• macroscale (3D) tissue (myrTissue) generated from the respective iPSC lines with properties of postnatal tissue for advanced screening and target validation.

• A highly parallelized phenotypic screening service (myrScreen).

myriamed has therefore two main types of activities, the generation of high-quality biological material allowing the research of new therapeutic targets, and the realization of customized phenotypic screenings.

To learn more about myriamed’s products please contact us:
https://bit.ly/2Di5ELG

About SV Puma: SV Puma Goettingen was founded in 1973 and is located in Göttingen in Germany. In both men's and women's soccer, the club offers bundled expert knowledge and playing soccer in a pleasant atmosphere with a colorful mix of students, trainees and professionals. The women's team currently plays in the district league. The two men's teams currently play in the 2nd and 3rd district class.

To learn more about SV Puma please visit:
https://bit.ly/Puma_eV

myriamed GmbH
Rudolf-Wissell-Str. 28a
37079 Göttingen
Tel.: +49 551 28878-170
Email: info@myriamed.com
Web: www.myriamed.com

myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release myriamed supports local soccer club here

News-ID: 2163679 • Views: 461

More Releases from myriamed GmbH

myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the
myriamed’s myrPlates are now also available from ZAGENO
We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace. myrPlates can be used for the generation of engineered human tissues. By parallel culture of up to 48 tissues in one myrPlate, e.g. contractile heart muscles or skeletal muscles can be obtained to serve numerous applications, such as drug screening and disease modelling. About myriamed: myriamed has unique expertise in research and development
Generation of Engineered Human Myocardium using myriamed myrPlates
In STAR Protocols Tibury et al. describe a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in 48 well myriamed myrPlates under defined, serum-free conditions (DOI: 10.1016/j.xpro.2020.100032). By parallel culture of up to 48 EHM in one myrPlate, contractile heart muscle can be obtained to serve numerous applications, such as drug screening and disease modelling, which are also offered by myriamed. The described protocol has

All 5 Releases


More Releases for Puma

New multi-channel central warehouse for Puma
Frankfurt am Main, 05.03.2019. Construction of a state-of-the-art multi-channel central warehouse in Geiselwind, Germany has begun for the sports company Puma. Miebach Consulting supported Puma in the tendering process, the awarding of contracts as well as in the concept review through simulation and now accompanies the implementation phase as sub-project manager for intralogistics. The new warehouse is scheduled to go into operation at the end of 2020. The European distribution center
Socks Market Is Booming Worldwide with Hanesbrands, Nike, Puma, Renfro
HTF MI recently introduced Global Socks Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Adidas, Asics, Balega, Drymax Technologies, Hanesbrands, Nike, Puma, Renfro, THORLO & Under
Global Athletic Footwear Market 2018 - Puma, Nike, Adidas, Asics
Apex Market Reports, recently published a detailed market research study focused on the “Athletic Footwear Market” across the global, regional and country level. The report provides 360° analysis of “Athletic Footwear Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Athletic Footwear on
Global Lightweight Jackets Market - PUMA, Adidas, Zara, NIKE & H&M
The Market Research Store report offers majority of the latest and newest industry data that covers the overall market situation along with future prospects for Lightweight Jackets market around the globe. The research study includes significant data and also forecasts of the global market which makes the research report a helpful resource for marketing people, analysts, industry executives, consultants, sales and product managers, and other people who are in need
Global Outdoor Jacket Market Research Report 2017: Nike, Adidas, PUMA
In this report, the global Outdoor Jacket market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Outdoor Jacket in these regions, from 2012 to 2022 (forecast), covering North
Sealing Coatings Market 2017- GRUPO PUMA, DRACO, COATNCOOL, Rialto
Sealing Coatings Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors. Sealing Coatings refers to the coating formed by the coating to prevent rain or groundwater leakage of a coating. Can be widely used in building roofing, basement, underground garage, indoor kitchen and toilet, water room, balcony, facade facade, slit,